598 results about "High avidity" patented technology

The invention relates to an anti-CD3 nano antibody, an anti-CD38 antibody and a bispecific antibody containing the anti-CD3 nano antibody and the anti-CD38 antibody. According to the invention, an anti-CD3 nano antibody and an anti-CD38 monoclonal antibody are excavated and prepared, humanized design is carried out to obtain antibodies with high affinity and specificity, and different configurations of bispecific T cell conjugation antibodies targeting CD3 and CD38 are further designed, so that the CD3 and CD38 dual-specificity T cell conjugation antibodies are obtained. The antigen binding activity, the T cell-mediated tumor cell killing effect and the T cell proliferation and activation function of the antibody are systematically evaluated in vitro, and experimental results show that the T cell conjugation antibody can effectively recruit and activate T cells and has a remarkable killing effect on CD38 positive tumor cells, and it is further verified that the antibody has remarkable in-vivo anti-tumor activity and has a good application prospect. Therefore, the polypeptide has high affinity, good pharmacological characteristics and development potential.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting measles virus nucleoprotein and application of the monoclonal antibody combination. The combination is composed of monoclonal antibodies 5E2 and 5G9 and can efficiently and specifically recognize measles virus nucleoprotein, amino acid sequences of complementary determining regions (CDR) of heavy chain and light chain variable regions of the combination are clear and are shown as SEQ ID NO.1-12 respectively, high specificity and high affinity of the antibodies are guaranteed, the antibody combination can effectively capture and detect target antigens, and the antibody combination can be used for detecting measles virus nucleoprotein. The risk of non-specific binding and cross reaction is obviously reduced. The combination shows excellent sensitivity and specificity in detection platforms such as colloidal gold immunochromatography, and provides a stable and reliable biological recognition tool for rapid and accurate detection of measles viruses.

The invention belongs to the technical field of biology, and particularly relates to a swine monoclonal antibody of hog cholera virus Erns protein. The amino acid sequence of a heavy chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 1, the amino acid sequence of a heavy chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 2, the amino acid sequence of a light chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 3, and the amino acid sequence of the light chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 4. The full-length genes of the heavy chain and the light chain of the swine monoclonal antibody are obtained from a swine B cell specifically amplified by the same hog cholera virus Erns protein, the natural structure of an antibody molecule is reserved, affinity loss possibly caused by artificial recombination is avoided, and the swine monoclonal antibody has high affinity and specificity, and can be used for preparing the swine monoclonal antibody. And a precise molecular tool is provided for antigen structure analysis of the hog cholera virus Erns protein and establishment of a hog cholera diagnosis method. The monoclonal antibody is applied to a blocking ELISA detection method of the hog cholera virus Erns antibody, and the established Erns antibody blocking ELISA detection method is high in sensitivity and strong in specificity.

The invention belongs to the technical field of nuclear medicine, and relates to a CAIX-targeted cyclic peptide and a preparation method and application thereof, the CAIX-targeted cyclic peptide structure is shown as a formula 1, Linker is a cyclization connexon, and Chenator is a nuclide chelating group. The CAIX-targeted cyclic peptide provided by the invention has high affinity with CAIX, and has low affinity with isoenzyme CAII of CAIX, so that the CAIX-targeted cyclic peptide has high selective affinity with CAIX; the nuclide-labeled radioactive probe has high labeling rate and excellent in-vitro stability, has excellent pharmacokinetic characteristics in tumor-bearing model mice of human renal clear cell carcinoma, and has extremely high tumor uptake, tumor-muscle ratio and tumor-kidney ratio which can meet diagnosis requirements; due to the long-time retention characteristic in tumors, the polymer has a relatively high tumor treatment application value.

The invention provides a multivalent Trop2 diagnosis probe and a preparation method and application thereof. The probe comprises a Trop2 specific multivalent nano antibody, and the Trop2 specific multivalent nano antibody is composed of a T4 monovalent nano antibody, a connexon and a tail end tag; the amino acid sequences of the T4 monovalent nano antibody, the connexon and the tail end tag are respectively as shown in SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3. According to the prepared multivalent Trop2 diagnostic probe, through a multivalent strategy, non-targeted organ uptake is reduced, and the signal-to-noise ratio during targeted imaging or treatment is increased; the probe has high affinity and high specificity to Trop2 in vivo, so that the probe can accurately recognize a focus. The probe can be used for noninvasive diagnosis of Trop2 expression positive tumors, and also has the advantages of simple preparation process, low cost, high specificity, high stability, easiness in clinical transformation and the like.

The invention relates to the field of antibodies, in particular to an anti-Der p 1 antibody and application thereof. The invention provides an anti-Der p 1 antibody, the anti-Der p 1 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises an amino acid sequence of a complementarity determining region, and the amino acid sequence of the complementarity determining region comprises CDR1 as shown in SEQ ID No.1, CDR2 as shown in SEQ ID No.2 and CDR3 as shown in SEQ ID No.3; or the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.8. The anti-Der p1 antibody provided by the invention is a monoclonal antibody with high affinity and high sensitivity, after the monoclonal antibody is subjected to humanized IgE transformation, the monoclonal antibody is applied to a Dermatophagoides pteronyssinus allergen component Derp1 specificity IgE magnetic particle chemiluminescence quantitative detection reagent, and a standard curve independently calibrated by the Dermatophagoides pteronyssinus allergen component Derp1 can be obtained; real, accurate and repeatable absolute quantification is realized, the Dermatophagoides pteronyssinus allergen component Derp 1 specificity IgE with the concentration of 0.1 IU / mL can be detected, and the method has clinical diagnosis significance in allergic reaction identification.

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

The invention relates to a construction method of a nanometer antibody coding DNA library. The method comprises the following steps: screening animal peripheral blood mononuclear cells (PBMC) by using immunogen to obtain positive cells specifically bound with the immunogen; and amplifying a nucleic acid sample derived from the positive cells so as to obtain a coding DNA library of the nano-antibody, wherein the nano antibody is a nano antibody specifically binding to the immunogen, and wherein the amplification comprises the use of one or more groups of primer pairs, each group of primer pairs of the one or more groups of primer pairs comprising one or more forward primers and one or more reverse primers. A large number of diversified DNA sequences covering a large number of low-abundance sequences are obtained. According to the technical route for rapidly preparing the VHH antibody based on high-throughput sequencing, the high-affinity and high-specificity VHH antibody can be efficiently and rapidly obtained, and the raw material requirement of a high-quality diagnostic reagent is met.

This invention belongs to the field of microcystin-LR detection technology, providing anti-microcystin-LR nanobodies and their applications. The anti-microcystin-LR nanobodies have amino acid sequences as shown in SEQ ID NO.1, SEQ ID NO.2, or SEQ ID NO.3. This invention uses phage display technology to screen for nanobodies with high affinity and high specificity for recognizing microcystin-LR, exhibiting advantages such as strong stability and ease of large-scale expression. Various detection tools can be designed based on anti-microcystin-LR, including test strips, immunoassay kits, immunoaffinity columns, biosensor detection chips, or detection probes. This provides novel antibody resources for rapid monitoring of microcystin-LR and lays a material foundation for developing low-cost, high-performance immunoassay technologies, which is of great significance for promoting the monitoring and control of microcystin-LR pollution.

HPV16 is a main cause of malignant tumors such as cervical cancer, and E6 protein of HPV16 becomes a key treatment and diagnosis target. In the prior art, an HPV16 detection antibody has the problems of poor stability, dependence on cold chain transportation, low preparation efficiency and the like. According to the invention, a nano antibody sequence which is high in affinity (dissociation constant KD is less than or equal to 1 * 10 <-7 > M) and stable at room temperature is obtained through total synthesis library construction and a phage-assisted directed evolution (PACE) screening technology. After the antibody is stored at 25 DEG C for 30 days, the activity of the antibody is kept to be greater than or equal to 95%, the antibody can be directly used for household test paper, the accuracy rate reaches 98%, and meanwhile, the antibody can be expanded to medical applications such as CAR-T cell therapy. Compared with a traditional antibody, the antibody has the advantages of being short in preparation period, low in cost, wide in application scene and the like, and a breakthrough solution is provided for early screening of cervical cancer.

The invention provides a simple and rapid preparation method of a novel HER2 targeted nano-drug maytansine (DM1). The preparation of the nano-drug is realized by using carboxyl on a side chain of azide-terminated poly (L-glutamic acid) (PLG) as a load binding site. The preparation method comprises the following steps: firstly, grafting N-(2-aminoethyl) maleimide hydrochloride (Mal-C2H4-NH2-HCL) to carboxyl of PLG (Poly L-Glycol), and introducing a maleimide group to form PLG-Mal; the preparation method comprises the following steps: preparing Fc-III-4C peptide-PLG-Mal (Fc-PLG-Mal) by virtue of an amidation reaction between carboxyl and amino of the Fc-III-4C peptide, and then carrying out thiol-maleimide click chemical reaction on a maleimide group and sulfydryl of DM1, so as to obtain the Fc-PLG-DM1. Finally, the HER2 antibody and the Fc-PLG-DM1 are mixed in water by utilizing the high affinity effect between the Fc-III-4C peptide and the Fc segment of the HER2 antibody, so that the HER2-PLG-DM1 can be obtained, and the HER2-PLG-DM1 has a remarkable tumor inhibition effect in animal experiments. The successful development of the HER2-PLG-DM1 proves the potential of the method in the design and development of functional nano-drugs in the future.

The invention relates to an anti-CD7 nano antibody and application thereof, the antibody comprises a heavy chain variable region, and the heavy chain variable region comprises CDR1, CDR2 and CDR3. According to the invention, the anti-CD7 antibody is screened, and the anti-CD7 antibody only comprises a heavy chain variable region, has high affinity and specificity, can efficiently target a CD7 antigen, is simple in structure and easy to prepare, and has important application value in the field of preparation of drugs taking CD7 as a target spot.

The invention relates to the technical field of safe conveying of oil and gas pipelines, in particular to a polypeptide type hydrate kinetic inhibitor screening method based on molecular simulation, which comprises the following steps: selecting target protein related to hydrate growth, and designing a polypeptide sequence; performing polypeptide pre-screening; evaluating the binding affinity and binding mode of the polypeptide and the target protein; performing MD simulation on the screened high-affinity polypeptide; verifying the binding affinity of the polypeptide and the target protein; and collecting all experiment and simulation data for statistical analysis, and optimizing the polypeptide sequence. The structure and function of the target protein are systematically analyzed by using a bioinformatics database and tools, it is ensured that the selected target plays an important role in hydrate formation, and meanwhile, a polypeptide sequence designed based on the target protein structure can effectively improve the binding capacity; and in the pre-screening and docking analysis process of the polypeptide, dynamic parameters are simulated and extracted by molecular dynamics, so that the interaction between the polypeptide and the target protein can be deeply understood.

The invention provides an anti-CD16a single-domain antibody and an application of the anti-CD16a single-domain antibody. In particular, the invention provides a specific single domain antibody for resisting human CD16a. The invention also provides a coding sequence for coding the single-domain antibody or the VHH chain thereof, a corresponding expression vector, a host cell and a method for producing the single-domain antibody. The single-domain antibody provided by the invention has high affinity and high specificity, and can be used for detection and targeted therapy of CD16a.

The invention relates to the technical field of biological medicines, and discloses a blocking antibody targeting CXCL6 and an application of the blocking antibody in preparation of antitumor drugs. The antibody or antigen-binding fragment thereof is capable of binding specifically to human CXCL6 protein with high affinity (e.g., Kd < = 1 nM). According to the invention, the specificity and high affinity of the antibody are verified by Western Blot, immunofluorescence, immunohistochemistry and surface plasmon resonance (SPR) technologies. Functional experiments show that the antibody can effectively block CXCL6-induced neutrophil chemotaxis, including in Transwell, a three-dimensional gel model and a zebra fish living body model. Besides, in a mouse MC38 colon cancer model, the antibody shows remarkable anti-tumor activity and can inhibit tumor growth driven by CXCL6. The invention also provides a pharmaceutical composition containing the antibody, and application of the antibody in preparation of drugs for preventing or treating diseases (such as inflammatory diseases, autoimmune diseases and cancers) related to abnormal expression or activity of CXCL6.

The application discloses a specific nucleic acid aptamer for a heterogeneous core ribonucleoprotein hnRNPA2B1 and application, and belongs to the technical field of nucleic acid aptamer. The hnRNPA2B1 aptamer is a small single-stranded DNA screened from a designed oligonucleotide library through an in-vitro exponential enrichment ligand system evolution (SELEX), is composed of 80 nucleotides, and has high affinity to the target. The hnRNPA2B1 aptamer can be applied in a detection method or a detection product of the hnRNPA2B1 protein, and a targeted regulation drug or a biological preparation, and can be specifically made into a molecular probe, used as a detection reagent, used as a targeted preparation and the like for diagnosis and treatment of diseases related to the hnRNPA2B1 protein. The hnRNPA2B1 aptamer has strong affinity and specificity, has the advantages of low production cost, stability, convenient synthesis and easy modification compared with an antibody, and is a potential substitute for the antibody in disease diagnosis and treatment.

The present disclosure provides anti-MerTK antibodies, variants and humanized forms thereof. The newly disclosed antibodies exhibit high affinity for MerTK protein and are useful for treating cancer, particularly solid tumors.

The present application relates to the technical field of biotechnology, in particular to a programmed death receptor ligand 2 monoclonal antibody and application thereof. The present application provides a PD-L2 monoclonal antibody, amino acid sequences of three CDR regions of a heavy chain thereof; amino acid sequences of three CDR regions of a light chain thereof; or amino acid sequences obtained by substitution, deletion or addition of one or more amino acids of the amino acid sequences, or amino acid sequences functionally identical or similar to the amino acid sequences; or amino acid sequences having at least 80% homology with the sequences. The present application widens the possibility of antibody therapy for blocking PD1 / PD1 ligand, and compared with existing PD-L2 monoclonal antibodies, the 8E3 antibody has unique amino acid sequences and CDR region sequences, high affinity and high specificity. The 8E3 antibody can be used in ELISA, Western blot and flow cytometry detection, and has wide application.

This invention belongs to the field of biomedical technology, specifically relating to a colorectal cancer antibody and its applications. The antibody is composed of a camel-derived VHH-3 single-domain antibody and a membrane-penetrating peptide TAT fused together via a flexible linker peptide (GGGGS)3, and its amino acid sequence is shown in SEQ ID NO:9. This invention uses phage display technology to screen for high-affinity VHH-3 (KD=0.9524 nM) and further constructs the membrane-penetrating nanobody TAT-VHH-3, achieving soluble and efficient preparation using a prokaryotic expression system. Experiments confirm that TAT-VHH-3 can significantly inhibit the proliferation (CCK-8 assay) and migration (scratch assay) of colorectal cancer Caco-2 cells in a concentration-dependent manner. The nanobody of this invention has advantages such as small molecular weight (approximately 16.1 kDa), strong penetrability, and high stability, providing a novel tool for tumor therapy targeting CaMKⅡα.

The application discloses a tandem antigen epitope peptide of G protein of Paralichthys olivaceus rhabdovirus and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO:1. The preparation method of the application comprises the following steps: (1) first, analyzing the structural characteristics of HIRRV-G protein and predicting B cell antigen epitopes, and synthesizing the antigen epitopes with advantages based on the prediction results; (2) then, screening candidate peptide segments with high affinity through enzyme-linked immunosorbent assay; (3) sequentially connecting the high-affinity peptide segment sequences meeting the requirements by using a GPGPG linker, and cloning the connected sequences into a pET-28a prokaryotic expression vector, so that the tandem antigen epitope peptide is obtained after induced expression. Compared with the full-length G protein, the tandem antigen epitope peptide has smaller molecular weight, stronger stability and stronger hydrophilicity; the tandem antigen epitope peptide can induce a large amount of specific antibodies in fish bodies, and significantly reduces the mortality of fish infected by the virus. The tandem antigen epitope peptide can be used for the development of HIRRV diagnostic reagents and subunit vaccines.

The present disclosure provides a nanobody platform having a high affinity purification on protein A, wherein the nanobodies may incorporate diverse bioactive peptides, lipid or glycoside in its CDR1 and / or CDR3 regions. The present disclosure also provides a peptide-modified nanobody comprising non-toxic bioactive peptides and that exhibit potent anti-tumor activity. Moreover, the peptide-modified nanobody is able to be combined with other technologies, such as but not limited to bispecific antibodies and antibody-drug conjugates. Further, the present disclosure also provides production processes of the nanobodies and their use as a treatment and diagnostic agents.

The invention relates to the field of antibodies, and particularly provides a high-affinity PADI2 antibody and a preparation method thereof. According to the invention, eight high-affinity PADI2 antibodies are obtained by screening through an antibody pair screening experiment, and the antibodies can be specifically combined with PADI2 protein and have high affinity. Experimental results show that the antibody disclosed by the invention shows excellent binding capacity in ELISA (Enzyme-Linked Immunosorbent Assay), Western blot and cell experiments, and can be used for detecting, diagnosing and treating PADI2 related diseases.

The embodiment of the invention discloses a heavy chain variable region and a light chain variable region of an anti-GPC3 monoclonal antibody and application of the heavy chain variable region and the light chain variable region. The high-affinity anti-GPC3 sequence is obtained through screening, the binding specificity of the high-affinity anti-GPC3 sequence and the GPC3 antigen is high, and dissociation is slow. The sequence is used as an extracellular targeting domain to construct GPC3-CAR, after macrophages are transduced through lentivirus, CAR-M can specifically recognize GPC3 positive target cells, activate intracellular signal channels and remarkably improve in-vitro phagocytosis and killing activity, the hepatoma cell lysis effect is better, and technical support is provided for anti-hepatoma application.

The application provides a nanobody targeting human transmembrane activator and calcium modulator and cyclophilin interactor (TACI) and an application thereof, and the antibody is derived from a llama heavy chain antibody variable region. The anti-TACI single-domain antibody NB38 can specifically bind to human TACI with high affinity, can recognize a recombinant TACI protein, can also recognize a TACI with a natural conformation on a cell surface, and can partially block a BAFF / APRIL signal pathway. Based on the nanobody, the application constructs a fusion protein, a chimeric antigen receptor, an effector cell expressing the chimeric antigen receptor, and a double-specific cell linker and other genetically engineered forms. The nanobody can be further extended into a drug coupling form. The product of the application can be used for mediating directional recognition and killing of TACI positive cells, and can be used as a supplement and expansion of BCMA targeted therapy, and provides a new candidate technical scheme for targeted therapy of multiple myeloma and other TACI related diseases.

The present application relates to the technical field of antibodies, in particular to a monoclonal antibody specifically targeting human SLC19A1 and application thereof.The present application provides a monoclonal antibody specifically targeting human SLC19A1 and application thereof.The present application obtains human SLC19A1 protein by expression and purification through a eukaryotic expression system; then uses the obtained SLC19A1 protein as an immunogen to immunize mice to generate antibodies; finally, a monoclonal antibody specifically recognizing and combining SLC19A1 protein is obtained through flow enrichment and screening, and the epitope recognized and combined by the antibody is identified.It is verified that the monoclonal antibody provided by the present application can specifically recognize and combine the amino acid residues of human SLC19A1 protein, has high affinity, can be used as a molecular tool for detection of SLC19A1 protein, has high sensitivity and specificity, and has application advantages in detection of human SLC19A1 protein.

The application relates to the technical field of computer-aided drug design, and provides a molecule generation method, system, medium and equipment for drug discovery, which comprises the following steps: acquiring a SMILES string of a ligand and an amino acid sequence of a target protein, respectively extracting a ligand feature vector and a protein feature vector, splicing and fusing, and then predicting a binding affinity value through a multilayer perception machine; taking the protein feature vector as a condition, generating a new molecular potential representation through a reverse denoising process of a conditional diffusion model; wherein, at each step of the reverse denoising process, a graph-level readout operation is performed on pure noise, an affinity value is predicted through the multilayer perception machine, a gradient of an affinity guidance loss is returned to a noise prediction network, and the new molecule generation is guided to a high affinity area; and the new molecular potential representation is decoded into a SMILES string through a pre-trained molecular language decoder. Novel molecules with high binding potential can be quickly generated.

The application belongs to the technical field of functional polypeptides, and particularly relates to an active peptide for senescent cells and a preparation method thereof, wherein the active peptide is obtained by molecular docking simulation screening and optimization with a helical structure segment in an IL-6R protein combined with a gp130 protein as a polypeptide template; the active peptide after functional optimization contains an FF unit driving nano self-assembly, a GFLG unit capable of being specifically cut by a lysosome protease highly expressed in a microenvironment of senescent cells, and an RYFQKWEKLRNQ unit generating high affinity with an IL-6 / IL-6R / gp130 complex; the designed active peptide itself has anti-aging activity and can also be used for synergistic delivery of drugs, and has a broad application prospect.

The invention belongs to the technical field of biomedicine and antibody engineering, and relates to a monoclonal antibody capable of being combined with human CD137 protein or a functional fragment of the monoclonal antibody, and application of the monoclonal antibody capable of being combined with the human CD137 protein or the functional fragment of the monoclonal antibody as an antibody conjugate, a chimeric antigen receptor and / or a composition. The monoclonal antibody is specifically combined with cell membrane surface CD137 protein and soluble CD137 protein through a specific nucleic acid sequence and an encoding antibody of the monoclonal antibody, has clear basic characteristics of CD137 combination specificity, sensitivity, affinity and the like, and can be used for detecting cell membrane surface CD137 and body fluid sCD137. The monoclonal antibody capable of being combined with the human CD137 protein, which is obtained by screening, has high sensitivity, high specificity and high affinity.

The application discloses a B cell immune repertoire antibody sequence feature analysis and specific screening method and related equipment, which can be applied to the technical field of data processing. According to the application, after the antibody sequencing sequence is subjected to germ line comparison and recognition to obtain corresponding first sequencing Fv sequence and germ line Fv sequence, the first sequencing Fv sequence is subjected to gene integrity filtering and structure integrity filtering, clonotype division and root node sequence reconstruction to obtain a second clonotype collection, and then a first lineage forest is constructed, and according to the second sequencing Fv sequence, the second clonotype collection or the first lineage forest, sequence feature analysis in multiple dimensions is carried out, so that the antibody sequence features can be analyzed from multiple dimensions such as sequence quality, sequence abundance, mutation degree, mutation preference and aggregation degree, the filtered BCR sequence has high affinity, and according to the sequence feature analysis results in multiple dimensions or the first lineage forest, a visualized graph is generated, so that relevant personnel can view the sequence features.

To provide a high-affinity monoclonal antibody for a His-tag added to the C terminus of membrane protein.SOLUTION: The present invention provides a monoclonal antibody for a histidine tag (His-tag) or an antigen-binding fragment thereof, wherein the monoclonal antibody recognizes, as an epitope, a His-tag added to the C terminus of a membrane protein.SELECTED DRAWING: None